Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Trump inflicts a £9bn blow to the UK drug sector with tariff threat
03:22am, Wednesday, 09'th Apr 2025
Donald Trump has inflicted a £9 billion blow on the UK drug sector. That's the collective impact on the valuations of AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK), which dropped sha
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
11:56am, Monday, 07'th Apr 2025
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
AstraZeneca's Innovation Ecosystem: From Blockbusters To The Next Generation Of Therapy
02:21am, Saturday, 05'th Apr 2025
AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company's diversified portfolio spans oncology, CVRM
Live Nasdaq Composite: FIVE Falls, AZN and PEP Rise From Tariff Ashes
09:30am, Friday, 04'th Apr 2025
The markets have succumbed to the tariff-fueled selling pressure, and there is nowhere to hide. President Trump’s tariff plan is intensifying the trade war. The Dow Jones Industrial is spiraling
VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned su
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
04:50pm, Thursday, 03'rd Apr 2025
As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst tradin
UK pharma escapes worst of Trump tariffs (for now) but uncertainty may keep pressure on shares
09:33am, Thursday, 03'rd Apr 2025
International pharma stocks GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) may have dodged a bullet under Donald Trump's sweeping new tariff regime, according to analysts at Shore Capital
AstraZeneca and GSK shares rise on possible escape from new US tariffs
05:12am, Thursday, 03'rd Apr 2025
UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that drug imports will escape the new 'recipr
AstraZeneca remains top pick with leading American bank. Here's why
10:02am, Wednesday, 02'nd Apr 2025
AstraZeneca PLC (LSE:AZN) has kept its spot as Bank of America's top pick in the pharmaceutical sector, with analysts raising their earnings forecasts and praising the company's “best-in-class” dr
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
01:47pm, Tuesday, 01'st Apr 2025
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
10:35am, Tuesday, 01'st Apr 2025
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
12:00pm, Monday, 31'st Mar 2025
AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. The results could buoy AstraZeneca stock.
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
03:20pm, Thursday, 27'th Mar 2025
The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid ca
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
10:35am, Thursday, 27'th Mar 2025
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
09:00am, Wednesday, 26'th Mar 2025
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, S
